2Stein AO,Donnell,Slovak M,et al,High dose cytosine arabinoside and daunorubicine induction for adult with de novo non M3 adult Myelogenous leukemia Leukemia,2000,14:1191.
3Harris NL,Jaffe ES,Diebold J,et aL The world health Organigation classfication of neoplastic diseases of the hematopoitic and lymphoid tissues.Ann oneol,1999,10:1419.
4NCCN.Clinical Practice guideline in oncology version 1,2004.
二级参考文献24
1Matthews DC, Appelbaum FR, Eary JF,et al. Phase I study of1311 -anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood, 1999,94:1237-1247.
2Ievers EL, Larson RA, Estey E, et al. Prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin (Mylotarg, CMA-676)followed by hemoatopoitic stem cell transplantation. Blood ,2000,96:320a.
3Lvarado Y, Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg, idarubicin and cytarabin combination regimen in patients with primary resistent oy relapsed acute myeloid leukemia. Cancer Chemother Pharmacol, 2003,51 (1): 87-90.
4Zwaan CM, Reinhardt D, Jurgens H, et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia, 2003,17: 468-470.
5Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogenic stem cell transplantation. Blood , 2003, 102 (5): 1578-1582.
6Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplant. Cancer, 2001,92(2) :406-413.
7Matsui H, Takeshita A, Natio K, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on p-glycoprotein and/or CD34 positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia, 2002,16: 813-819.
8Matthews DC, Appelbaum FR , Eary JF, et al. Phase I study of 131-I-anti-CD45 antibodies plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood , 1999,94:1237-1247.
9Sievers EL , Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of anti-CD33 calicheamicin immunoconjugate. Blood , 1999,93: 3678-3684.
10Feldman E, Kalaycio M,Schulmn P, et al. Humanized anti-CD33monoclonal antibody HuM195 Treatment of relapsed/refractory acute myeloid leukemia(AML): preliminary report of a phase Ⅱstudy. Proc Am Soc Clin Oncol, 1999,18:4a.
